Text Size

GLP1R Polymorphisms and Response to GLP1

This study has been completed.
Sponsor:
Collaborator:
Merck
Information provided by (Responsible Party):
Adrian Vella, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00588380
First received: December 22, 2007
Last updated: December 14, 2011
Last verified: December 2011
History of Changes
Results First Received: April 4, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Basic Science
Condition: Diabetes
Intervention: Drug: GLP-1

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Healthy volunteers recruited from Olmsted County, MN.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Overall Study All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.

Participant Flow:   Overall Study
    Overall Study  
STARTED     88  
COMPLETED     88  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Overall Study All participants recieved glucose for 2 hours then Glucagon Like Peptide-1 (GLP-1) intravenously at a rate of 0.75 pmol/kg/min for 1 hour followed by 1.5 pmol/kg/min for the subsequent hour. The study lasted for 240 minutes.

Baseline Measures
    Overall Study  
Number of Participants  
[units: participants]
 		  88  
Age  
[units: years]
Mean ± Standard Deviation 		  26.3  ± 5.6  
Gender  
[units: participants]
 		 
Female     52  
Male     36  
Region of Enrollment  
[units: participants]
 		 
United States     88  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Insulin Secretion at 150-180 Minutes.   [ Time Frame: 150 - 180 minutes after GLP-1 infusion ]
  Show Outcome Measure 1

2.  Secondary:   Insulin Secretion at 210-240 Minutes   [ Time Frame: 210 - 240 minutes after GLP-1 infusion ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This is a pilot study with limited power to detect / replicate effects. It will require independent replication of study results.  


Results Point of Contact:  
Name/Title: Adrian Vella
Organization: Mayo Clinic
phone: 507-284-3754
e-mail: vella.adrian@mayo.edu


Publications of Results:


Responsible Party: Adrian Vella, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00588380     History of Changes
Other Study ID Numbers: 07-004153
Study First Received: December 22, 2007
Results First Received: April 4, 2011
Last Updated: December 14, 2011
Health Authority: United States: Food and Drug Administration